RBC Capital Remains a Buy on HCA Healthcare (HCA)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Hendrix covers the Healthcare sector, focusing on stocks such as Cigna, HCA Healthcare, and Humana. According to TipRanks, Hendrix has an average return of 3.2% and a 48.41% success rate on recommended stocks.
HCA Healthcare has an analyst consensus of Moderate Buy, with a price target consensus of $395.33, implying a 6.33% upside from current levels. In a report released on July 10, Barclays also maintained a Buy rating on the stock with a $416.00 price target.
The company has a one-year high of $417.14 and a one-year low of $289.98. Currently, HCA Healthcare has an average volume of 1.47M.
Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HCA in relation to earlier this year. Most recently, in May 2025, Jon Foster, the EVP & COO of HCA sold 15,698.00 shares for a total of $5,797,585.36.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Dexcom Launches Revolutionary AI-Powered Meal Logging Feature Across Glucose Biosensing Portfolio
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc., the global leader in glucose biosensing, announced today it has released a new AI-powered photo meal logging feature to Stelo, the first over-the-counter glucose biosensor cleared 1 by the FDA in the United States, following the feature's launch on Dexcom G7 earlier this year. Dexcom's Smart Food Logging feature encourages and enables users to log their meals more consistently. Stelo and Dexcom G7 users can now simply take a photo of their food in the app where AI will automatically identify the ingredients and populate the meal description. Dexcom G7 is the only prescription continuous glucose monitor in the U.S. to support photo logging 2,3. 'Diet plays a crucial role in managing glucose levels, and our new Smart Food Logging feature removes barriers to food tracking, making it easier to consistently log and understand the impact of meals,' said Jake Leach, president and chief operating officer at Dexcom. 'Smart Food Logging has long been a highly requested feature from users across our product portfolio, so we're excited to bring it to market and hope this enhanced tracking feature makes managing glucose levels even simpler.' The addition of Smart Food Logging is yet another demonstration of Dexcom's commitment to continued innovation and AI. This new feature joins other recently announced enhancements across Dexcom's glucose biosensing portfolio, including: Weekly Insights in Stelo: The first GenAI feature in Stelo, which offers users more personalized tips, recommendations, and education related to diet, exercise, and sleep that are contextualized within the Stelo app. Stelo integration with Oura: The first-ever integration of glucose biosensing data in the Oura app. When Stelo is synced with Oura, users have a holistic view of their body's biometrics, now including glucose. This integration empowers users to understand the impact of different health behaviors and work towards optimal metabolic health. Customizable target range in Dexcom G7: A new feature that enables users to adjust their glucose target ranges in Clarity Card within the Dexcom G7 app, beyond default settings – allowing for greater personalization across user groups. Glucose Impact in Dexcom G7 and Stelo: Glucose Impact offers a new focused view for logged events to see a clearer picture and gain a deeper understanding of how meals, activities, and sleep patterns affect your glucose levels. Stelo and Dexcom G7 users can now access the Smart Food Logging feature by updating to the latest version of the app on iOS and Android platforms. About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Dexcom. Discover what you're made of. For more information, visit Category: IR Freestyle Libre User Guides. 3 Based on Medtronic User Guides.
Business Insider
4 hours ago
- Business Insider
Kepler Capital Reaffirms Their Buy Rating on Neste Corporation (0O46)
Kepler Capital analyst Pablo Cuadrado maintained a Buy rating on Neste Corporation on July 24 and set a price target of €13.80. The company's shares closed last Friday at €14.61. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Cuadrado is a 4-star analyst with an average return of 7.6% and a 56.55% success rate. Cuadrado covers the Industrials sector, focusing on stocks such as Bureau Veritas, Construcciones y Auxiliar de Ferrocarriles, and SGS SA. In addition to Kepler Capital , Neste Corporation also received a Buy from Goldman Sachs's Michele Della Vigna in a report issued on July 25. However, on the same day, Banco Santander downgraded Neste Corporation (LSE: 0O46) to a Hold.
Business Insider
4 hours ago
- Business Insider
Boss Energy (BQSSF) Gets a Hold from Macquarie
Macquarie analyst maintained a Hold rating on Boss Energy today and set a price target of A$4.45. The company's shares closed last Friday at $2.39. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. In addition to Macquarie, Boss Energy also received a Hold from RBC Capital's Alistair Rankin in a report issued on July 17. However, today, Morgan Stanley downgraded Boss Energy (Other OTC: BQSSF) to a Sell. The company has a one-year high of $3.11 and a one-year low of $1.26. Currently, Boss Energy has an average volume of 23.73K.
